This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The increased use of radiofrequency ablation (RFA) for atrial fibrillation (AF) has led to a rise in cases of pulmonary vein stenosis or occlusion (PVS/O) as a complication. The actual frequency of pulmonary vein (PV) occlusion remains a topic of debate.
1,2 People living with AFib face an increased risk of stroke, heart failure and death, and many rely on cardiac ablation to treat the condition effectively. The trial showed the Volt PFA System achieved pulmonary vein isolation (PVI) the method of destroying tissue causing a patient's AFib in 99.1% Procedural flexibility.
Pulmonary vein isolation (PVI) is the cornerstone of interventional treatment for atrial fibrillation (AF). Pulsed-field ablation (PFA), a novel non-thermal modality, was recently introduced and is now available with four different FDA-approved systems from three different manufacturers.
Superior vena cava (SVC) conduction delay or isolation during right superior pulmonary vein (RSPV) ablation using thermal ablation technologies has been previously described.1,2 1,2 No reports regarding the impact of pulsed-field ablation (PFA) on the SVC exist.
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. Early recurrence of atrial tachyarrhythmia (ERAT) is commonly seen following catheter ablation of AF, with reported incidences of up to 61% in the first three months.
a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the Heart Rhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024. milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. ,
Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System. A company statement reported that its PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e.,
Ablation index (AI)-guided pulmonary vein isolation (PVI) has enhanced procedural outcomes for atrial fibrillation (AF).1 1 However, patients with persistent AF present higher recurrence rates due to advanced atrial remodeling,2-3 represented by the left atrial low voltage area (LVA), compared to those with paroxysmal AF.
Distribution Variance of Focal Atrial Tachycardia Foci and Long-Term Outcomes After Ablation. We aimed to evaluate age differences in foci and factors influencing recurrence after radiofrequency catheter ablation in adult and juvenile patients with FAT. After a mean follow-up of 47.2 months, FAT recurred in 57 patients.
(MedPage Today) -- The FDA approved the Farapulse pulsed field ablation (PFA) system for paroxysmal atrial fibrillation (Afib or AF), Boston Scientific announced on Wednesday. The device won an indication for the isolation of pulmonary veins in.
Pulsed field ablation (PFA) is selective for the myocardium. However, vagal responses and reversible effects on ganglionated plexi (GP) are observed during pulmonary vein isolation (PVI). Anterior-right GP ablation has been proven to effectively prevent vagal responses during radiofrequency-based PVI.
Pulmonary vein isolation (PVI) is the most effective treatment for rhythm control. Atrial fibrillation is the most prevalent arrhythmia with a lifetime risk of nearly 30%. It can be associated with reduced quality of life and complications such as heart failure and stroke. It has initially been performed with fluoroscopic catheter guiding.
The international, multi-center trial will provide clinical evaluation of Cortex's 510(k) cleared Ablamap System with electrographic flow (EGF) and newly released Ablacath Mapping Catheter basket mapping catheter to identify extra-pulmonary vein EGF sources. and may enroll up to 400 subjects across 20+ centers in the US and Europe.
(MedPage Today) -- LONDON -- Pulmonary vein isolation (PVI) produced real short-term improvements for people with atrial fibrillation (Afib or AF), according to the first sham-controlled trial on the subject. Continuous monitoring by implantable.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
Focal coronary spasm is a recognised complication of pulsed field ablation (PFA) delivered within proximity of coronary arteries (1). There have been 2 recent case reports of focal spasm occurring during pulmonary vein isolation (PVI) for atrial fibrillation (AF) using PFA remote from coronary arteries (2,3).
Despite the relative efficacy of ablation, the risk of AF recurrence is substantial, particularly in patients with persistent AF (perAF). At present we do not have any reliable intra-procedural electrophysiologic predictors of long-term success of AF ablation other than pulmonary vein isolation.
Launching the first FDA -approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency 1. In my clinical experience with the catheter, it was designed for AF ablation procedures.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S. Circulation.
Pulsed field ablation (PFA) for paroxysmal atrial fibrillation (AF) has been gaining worldwide acceptance due to its efficacy and safety. However, the role of TPI during pulmonary vein (PV) isolation (PVI) is unclear. A variable loop circular catheter (VLCC, VARIPULSE, Biosense Webster, Inc.)
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.
BackgroundCatheter ablation is frequently used to manage recurrent atrial fibrillation (AF) resistant to drug therapy, with pulmonary vein isolation (PVI) as a key tactic. The reconnection of pulmonary veins was discovered primarily in the anterior region of the right superior PV and the superior portion of the left superior PV.
What is the real-world lesion durability of pulmonary vein isolation (PVI) with pulsed-field ablation (PFA) among patients with clinically indicated redo procedures?
Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. min vs. 23.76 ± 8.36 min, The rate of 12-month freedom from clinical atrial arrhythmia recurrence was 85.1%
The results of pulmonary vein isolation are limited by arrhythmia recurrence, which is most often due to a failure to effectuate a durable contiguous circumferential transmural lesion around the pulmonary vein (PV) ostia.
Abstract Introduction Some previous studies have reported that a first-step ethanol infusion into the vein of Marshall (EIVOM) with touch-up radiofrequency (RF) ablation can facilitate mitral isthmus (MI) block and improves the ablation outcomes in persistent atrial fibrillation (PeAF) patients. 0.78, p = .006).
Objectives This study aimed at exploring how using different kinds of sheaths will affect the very first ablation procedure of apprentices. Methods 15 patients with paroxysmal atrial fibrillation were randomized to used fixed-curve, conventional steerable or visualized steerable sheath, and received complete isolation of pulmonary veins.
Pulsed field ablation (PFA) is a new treatment for atrial fibrillation (AF), and its selective ablation characteristics give it a significant advantage in treatment. In previous cellular and animal experiments, we have demonstrated that biphasic asymmetric pulses can be used to ablate myocardial tissue.
The AFib pulsed field ablation treatment era officially began in the US last week, following the FDA approval of Medtronic’s PulseSelect Pulsed Field Ablation System for the treatment of both paroxysmal and persistent atrial fibrillation. PFA systems use electroporation (short electrical pulses) to achieve pulmonary vein isolation.
Initial findings from feasibility studies on pulsed field ablation (PFA) in the treatment of atrial fibrillation (AF) indicated high rates of efficacy and pulmonary vein (PV) isolation (PVI) durability upon systematic remapping.
Ablation index (AI)-guided pulmonary vein isolation (PVI) has been widely performed in catheter ablation of atrial fibrillation (AF). Recently, a temperature-controlled ablation catheter (QDOT MICRO, Biosense Webster, Inc) had been introduced, enabling very high-power short-duration (vHPSD) ablation.
Pulmonary vein isolation (PVI) by pulsed-field ablation (PFA) has demonstrated encouraging clinical results for the treatment of atrial fibrillation (AF)1,2. This study aims to assess procedural characteristics, safety, and clinical outcomes of PFA-based PVI in patients with a LCPV.
Background Catheter ablation (CA) for symptomatic atrial fibrillation (AF) offers the best outcomes for patients. Despite the benefits of CA, a significant proportion of patients suffer a recurrence; hence, there is scope to potentially improve outcomes through technical innovations such as ablation index (AI) guidance during AF ablation.
Electroanatomic mapping guides complex atrial tachycardia ablations; however, challenges may emerge after pulmonary vein isolation. 3D mapping systems can reveal the mechanism of tachycardia and critical areas that need to be ablated.
Pulmonary vein isolation (PVI) is the cornerstone ablation treatment for AF. However, non-pulmonary vein (non-PV) triggers can sustain AF, and their identification and ablation remain challenging.
While atrial fibrillation (AF) ablation has advanced to improve safety, success rates have been slower to improve. Factors contributing to this include the failure to personalize ablation strategies for individuals. 1,2) Despite this, no patient-specific factors have been consistently identified to predict either of these outcomes.
Pulsed field ablation (PFA) has emerged as an alternative energy source for catheter ablation for atrial fibrillation. However, aiming for pulmonary vein (PV) isolation may lead to recurrence due to one small arrhythmogenic reconnection. We have previously demonstrated the safety of ablation within the PVs.
Background: Patients with atrial fibrillation (AF) and concomitant pulmonary hypertension (pHTN) have an increased risk of morbidity and mortality. However, the outcomes of catheter ablation in this cohort are unclear.
We previously reported that first-pass pulmonary vein (PV) isolation (FPI) is related to the PV isolation (PVI) durability in ablation index (AI) guided catheter ablation for atrial fibrillation (AF) (J Cardiovasc Electrophysiol 2023). However, the impact of obesity on FPI has been scarcely reported.
Pulmonary vein (PV) isolation is the cornerstone of radiofrequency (RF) ablation for atrial fibrillation (AF). PV reconnection is the most common cause of recurrent AF following an ablation procedure. Additionally, the relationship between impedance drop during ablation lesion delivery and PV ostial WT is not well understood.
Research conducted across 12 hospitals in China has discovered that combining linear ablation with ethanol infusion via the vein of Marshall (EIVOM) alongside pulmonary vein isolation (PVI) significantly improves sinus rhythm maintenance in patients suffering from persistent atrial fibrillation.
The VARIPULSE Platform is comprised of the VARIPULSE Catheter, a fully integrated variable-loop multielectrode catheter; the TRUPULSE Generator, a pulsed field ablation (PFA) generator; and the CARTO 3 System VARIPULSE Software, which provides full integration with the world's leading 3D cardiac mapping system.
In this week’s View, Dr. Eagle looks at the durability of pulmonary vein isolation using pulsed-field ablation, then examines genetic penetrance of dilated cardiomyopathy in genotype-positive relatives.
Pulsed field ablation (PFA) is a novel, nonthermal, cardiac tissue selective ablation modality. To date, radio-frequency (RF) guided high-power-short-duration (HPSD) ablation represents the gold standard for pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content